New treatments for methicillin-resistant Staphylococcus aureus

Current Opinion in Critical Care

Volumn 15, Issue 5, 2009, Pages 403-412

  Stryjewski, Martin E ^a,b   Corey, G Ralph ^a,c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CEMIC   (Argentina)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Investigational drugs; Methicillin resistant staphylococcus aureus; New therapies; Treatment

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; DAPTOMYCIN; DIHYDROFOLATE REDUCTASE INHIBITOR; ICLAPRIM; LINEZOLID; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; TELAVANCIN; TIGECYCLINE;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DAPTOMYCIN; EVIDENCE-BASED MEDICINE; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; OXAZOLIDINONES; PYRIMIDINES; STREPTOCOCCAL INFECTIONS;

EID: 70350117988     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32832f0a74     Document Type: Review

References (79)

1. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40:562-573.
2. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (Suppl 5):S344-S349. An elegant review describing important epidemiological changes of MRSA infections.
3. Rosenthal VD, Maki DG, Mehta A, et al. International nosocomial infection control consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36:627-637.
4. Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727-736.
5. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-3886.
6. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. This study provides strong evidence that higher MICs to vancomycin are associated with worse clinical outcomes in patients with bloodstream infections due to MRSA. (Pubitemid 351269157)
7. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493-501.
8. Centers for Disease Control and Prevention (CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin: Japan, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:624-626.
9. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-567.
10. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008; 46:675-677.
11. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-1673.
12. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605-609.
13. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-1347.
14. Moellering RC Jr. The growing menace of community-acquired methicillinresistant Staphylococcus aureus. Ann Intern Med 2006; 144:368-370.
15. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674.
16. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-317.
17. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (Suppl 5):S368-S377. A comprehensive review on SSSIs due to community-acquired MRSA.
18. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA2007;298:1763-1771.
19. Jenkins TC, McCollister BD, Sharma R, et al. Epidemiology of healthcareassociated bloodstream infection caused by USA300 strains of methicillinresistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol 2009; 30:233-241.
20. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42:3251-3255.
21. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000; 59:7-16.
22. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-142.
23. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:1475-1480.
24. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilatorassociated pneumonia. Crit Care Med 2005; 33:1529-1533. (Pubitemid 40980608)
25. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillinresistant Staphylococcus aureus. J Infect Dis 2007; 195:202-211.
26. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-2266.
27. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-412.
28. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-992.
29. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797.
30. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134:1200-1207.
31. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490.
32. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009; 48:203-212. This randomized clinical trial in patients with catheter-related bacteremia has shown a higher mortality in the linezolid arm, specifically in patients with mixed Gram-positive and Gram-negative infections. A plausible explanation is still unknown.
33. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospitalassociated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2974-2976.
34. Hope R, Livermore DM, Brick G, et al. Nonsusceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-2006. J Antimicrob Chemother 2008; 62 (Suppl 2):ii65-ii74.
35. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-208.
36. Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27:300-302.
37. Hentschke M, Saager B, Horstkotte MA, et al. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 2008; 36:85-87.
38. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39:1010-1015.
39. Stein GE. Safety of newer parenteral antibiotics. Clin Infect Dis 2005; 41 (Suppl 5):S293-S302.
40. Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004; 38:1058-1064.
41. Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008; 62:407-410.
42. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46 (Suppl 5):S386-S393. Comprehensive recommendations in the management of patients with S. aureus bacteremia.
43. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
44. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
45. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665.
46. Levine D, Hoffman-Roberts H, Brown J, Lamp K. Outcomes with daptomycin for infective endocarditis [abstract #L-1518]. 48th ICAAC/IDSA 46th Annual Meeting, Washington, District of Columbia; 2008.
47. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120 (10 Suppl 1):S28-S33.
48. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-2152.
49. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of communityacquired pneumonia. Clin Infect Dis 2008; 46:1142-1151. This randomized clinical trial demonstrated that daptomycin was inferior to ceftriaxone in the treatment of patients with community-acquired pneumonia.
50. Castanheira M, Jones RN, Sader HS. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis 2008; 61:235-239.
51. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601-608.
52. Patel JB, Jevitt LA, Hageman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42:1652-1653.
53. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42:e108-e110.
54. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44: 2948-2953.
55. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 (Suppl 5):S303-S314.
56. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-524.
57. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl 5):S341-S353. (Pubitemid 41170381)
58. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 (Suppl 1):i17-i28.
59. Maroko R, Cooper A, Dukart G, et al. Results of phase 3 study comparing a tigecycline regimen with an imipenem/cilastatin regimen in treatment of patients with hospital-acquired pneumonia [abstract #L-730]. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois; 2007.
60. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63:52-61.
61. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008; 30:2040-2050.
62. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127-1134.
63. Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008; 9:2197-2207.
64. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-1693. These randomized clinical trials demonstrated that telavancin was noninferior to vancomycin in patients with cSSSIs.
65. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for the treatment of hospital-acquired pneumonia caused by MSSA and MRSA: the ATTAIN studies [abstract #K-530]. 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, District of Columbia; 2008. These randomized clinical trials demonstrated that telavancin was noninferior to vancomycin in patients with hospital-acquired pneumonia due to S. aureus.
66. Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008; 46:577-583.
67. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-1415.
68. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by grampositive pathogens. Clin Infect Dis 2005;40:374-380.
69. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004;64:913-936.
70. FDA briefing document. Antiinfective Drug advisory Committee; 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-03-FDA.pdf. [Accessed 4 March 2009].
71. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum antimethicillinresistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008;42:806-816.
72. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647-655.
73. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44. This randomized clinical trial demonstrated that ceftobiprole was not inferior to vancomycin in patients with cSSSIs.
74. Noel GJ, Strauss RS, Shah A, Bagchi P. Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia [abstract #K-486]. 48th Annual ICAAC/IDSA 46th Annual Meeting; 2008. Washington, District of Columbia. This randomized trial showed that ceftobiprole was inferior to the comparator in the subgroup of patients with VAP.
75. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Grampositive activity. Future Microbiol 2009; 4:25-33.
76. Corey R, Wilcox M, Talbot GH, et al. CANVAS-1: randomized, double-blind, phase 3 study, of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections [abstract #L-1515]. 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, District of Columbia; 2008. A randomized clinical trial showing that ceftaroline is noninferior to vancomycin in patients with SSSIs.
77. Laue H, Weiss L, Bernardi A, et al. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 2007;60:1391-1394.
78. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13:4217-4221.
79. Advisory Committee Briefing Book; 2008. http://www.fda.gov/ohrms/dockets/ ac/08/briefing/2008-4394b3-03-ARPIDA.pdf. [Accessed 8 March2009].